GSK gets expanded EU approval for Jemperli in endometrial cancer

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer.

EU regulators have approved the product for use in combination with chemotherapy as a first-line treatment